Our data also suggest that pre- and post-operative bevacizumab treatment, in addition to metastatic tumor resection, may provide survival benefits in patients with mCRC and KRAS mutations and should therefore be considered in this setting. This evidence concerns the gene KRAS and metastatic neoplasm.